|
|||||
|
|
| 内分泌治疗对乳腺癌患者骨密度影响的研究进展 | |
| 引用本文： | 徐小玉 朱海波 王玲. 内分泌治疗对乳腺癌患者骨密度影响的研究进展[J]. 中国骨质疏松杂志, 2013, 0(10): 1104-1107 |
| 作者姓名： | 徐小玉 朱海波 王玲 |
| 作者单位： | 大连医科大学附属第一医院 大连116011 |
| 摘 要： | 雌、孕激素受体（ER、PR）阳性的浸润性乳腺癌患者，均应接受内分泌治疗。内分泌治疗疗效好，但有其相应的不良反应，骨密度（bone mineral density，BMD）降低是内分泌治疗的主要不良反应之一。本文主要介绍乳腺癌内分泌治疗对患者骨密度的影响方面研究进展。 |
| 关 键 词： | 乳腺癌；内分泌治疗；骨密度；双膦酸盐；地诺单抗 |
Research progress of the effect of endocrine therapy on bone mineral density in patients with breast cancer |
|
| XU Xiaoyu,ZHU Haibo,WANG Ling. Research progress of the effect of endocrine therapy on bone mineral density in patients with breast cancer[J]. Chinese Journal of Osteoporosis, 2013, 0(10): 1104-1107 | |
| Authors: | XU Xiaoyu ZHU Haibo WANG Ling |
| Affiliation: | The First Hospital Affiliated to Dalian Medical University, Dalian 116021, China |
| Abstract: | Endocrine therapy usually should be implemented to invasive breast cancer patients with hormone receptor-positive (ER, PR). Clinical efficacy of endocrine therapy is good, while relvant side effects also exist. The decrease of bone mineral density (BMD) is one of the main side effects in patients receiving endocrine therapy. This paper mainly focuses on the research progress of the effect of endocrine therapy on BMD of patients with breast cancer. |
| Keywords: | Breast cancer Endocrine therapy Bone mineral density Diphosphonates Denosumab |
| 点击此处可从《中国骨质疏松杂志》浏览原始摘要信息 | |
| 点击此处可从《中国骨质疏松杂志》下载免费的PDF全文 | |